Related Experiment Video
Updated: Aug 14, 2026
Global and Current Research Trends of Single-Cell Sequencing in Cancer: A Bibliometric and Visualization Study
Published on: April 18, 2025
Global research trends and thematic evolution in neoadjuvant therapy and surgery for non-small cell lung cancer: a
Xinyu Wu1, Wensi Zhao1, Xiang Cheng1
1Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, China.
Background:
Neoadjuvant therapy has become a cornerstone of curative-intent management for resectable non-small cell lung cancer (NSCLC), particularly since immune checkpoint inhibitors and biomarker-guided strategies entered perioperative practice. However, the field's global knowledge structure, collaboration architecture, and surgery-relevant thematic transitions have not been comprehensively mapped.
Methods:
Publications on neoadjuvant/induction/preoperative therapy and surgery for NSCLC (January 1989 to September 2025) were retrieved from the Web of Science Core Collection, PubMed, and Wanfang. Bibliometrix, VOSviewer, and CiteSpace were used to quantify productivity and impact, map collaboration and coupling networks, and identify co-citation clusters and citation/keyword bursts. Latent Dirichlet Allocation (LDA; k=8) was applied to abstracts and keywords to characterize semantic domains and their evolution.
Results:
A total of 1,512 publications were included. China and the United States were the dominant contributors and citation hubs. European countries showed higher proportions of multinational collaborations. Core journals formed a dual source landscape bridging thoracic surgery and oncology/immunology. Co-citation clustering showed strong structural validity and highlighted the rise of neoadjuvant chemoimmunotherapy, perioperative safety, and pathological response endpoints. LDA confirmed a shift from induction chemotherapy/chemoradiotherapy toward immunotherapy-centered perioperative paradigms and translational monitoring. Surgery-facing synthesis of representative landmark studies emphasized evolving emphases on complete resection, downstaging, and lung-sparing operative strategies.
Conclusions:
From January 1989 to September 2025, neoadjuvant NSCLC research transitioned from cytotoxic induction to immunologically driven, biomarker-informed perioperative paradigms tightly integrated with surgery. This integrated bibliometric-semantic framework provides a reproducible approach to monitor emerging fronts and to translate research signals into clinically interpretable questions for multidisciplinary perioperative decision-making.
Insights
Neoadjuvant therapy for non-small cell lung cancer (NSCLC) has shifted from chemotherapy to immunotherapy, integrating biomarkers and surgery. This research maps the evolution of perioperative paradigms for improved patient outcomes.
Area of Science:
- Oncology
- Thoracic Surgery
- Immunology
Background:
- Neoadjuvant therapy is crucial for resectable non-small cell lung cancer (NSCLC).
- The integration of immune checkpoint inhibitors and biomarker-guided strategies has transformed perioperative practice.
- A comprehensive mapping of the field's knowledge structure, collaborations, and thematic shifts is lacking.
Purpose of the Study:
- To map the global knowledge structure and collaboration architecture of neoadjuvant therapy for NSCLC.
- To identify thematic transitions and evolving research fronts in the field.
- To provide a framework for translating research signals into clinical decision-making.
Main Methods:
- Bibliometric analysis of 1,512 publications (1989-2025) from Web of Science, PubMed, and Wanfang.
- Network analysis using Bibliometrix, VOSviewer, and CiteSpace to map collaborations and co-citations.
- Latent Dirichlet Allocation (LDA) to analyze semantic domains and their evolution.
Main Results:
- China and the US are leading contributors; European countries show strong multinational collaboration.
- Co-citation analysis reveals the rise of neoadjuvant chemoimmunotherapy, perioperative safety, and pathological response.
- LDA demonstrates a shift from induction chemotherapy/chemoradiotherapy to immunotherapy-centered perioperative approaches.
Conclusions:
- Neoadjuvant NSCLC research has evolved from cytotoxic induction to biomarker-informed, immunotherapy-driven perioperative paradigms.
- The study provides an integrated bibliometric-semantic framework to monitor research trends.
- This framework aids in translating research into clinically relevant questions for multidisciplinary care.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:21Cancer Survival Analysis